Please ensure Javascript is enabled for purposes of website accessibility

Why ImmunoGen Stock Is Crushing It Today

By Keith Speights - Nov 5, 2019 at 10:29AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investors appear to have renewed hopes for the biotech's experimental ovarian cancer drug.

What happened

Shares of ImmunoGen (IMGN 1.86%) were soaring 14.8% higher as of 11:20 a.m. EST on Tuesday. The biotech provided its third-quarter update last Friday. While its financial results were nothing to get excited about, investors cheered its progress with a late-stage clinical study evaluating mirvetuximab soravtansine in treating platinum-resistant ovarian cancer patients whose tumors express high levels of folate receptor alpha. ImmunoGen stock rallied after its Q3 update, with the momentum continuing through today.

So what

There can be a "follow the herd" mentality with investing in stocks. That can especially be the case for small-cap biotechs like ImmunoGen.

Man holding hand with image of a arrow pointing up and bar chart trending up appearing over his palm

Image source: Getty Images.

It has endured a rough stretch since announcing in March that mirvetuximab failed to meet the primary endpoint in its Forward I phase 3 study in treating ovarian cancer. But the company's update on Friday that it expects to soon enroll the first patient in another late-stage study for the drug -- one that CEO Mark Enyedy said could increase the chances of a positive outcome -- is certainly good news for the beleaguered biotech.

Investors responded to Enyedy's optimistic outlook with a spark of hope that mirvetuximab still has a shot at success. And it seems that this spark has become a flame with even more investors scooping up shares, with renewed optimism about the biotech's prospects.

Now what

It's still way too early to know how mirvetuximab will actually fare in the current late-stage study targeting ovarian cancer. Buying ImmunoGen stock at this point is very risky and something that only aggressive investors will even want to consider.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

ImmunoGen, Inc. Stock Quote
ImmunoGen, Inc.
$4.39 (1.86%) $0.08

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.